
Palaszczuk Government boosts manufacturing capability for Ellume’s world-class COVID-19 rapid tests
Highlights
- Ellume receives strategic investment from Queensland State Government under Essential Goods and Supply Chain Program
- State Government funding will enable expansion of Ellume’s Brisbane manufacturing facility, the largest of its kind in the Southern Hemisphere
- Ellume will install multiple state-of-the-art automated production lines to speed up and enhance production capability
- Production is already underway and Ellume is on-track to ship over 100,000 tests per day from next month, Ellume plans to manufacture and deliver 20 million Ellume COVID-19 tests within the first half of 2021
Brisbane, Australia – 8 December 2020
Digital diagnostics company Ellume today announced a strategic investment by the Queensland State Government under their $50 million Essential Goods and Supply Chain Program. The funding will allow the company to ramp up production of its range of rapid diagnostic tests for common infectious diseases, including COVID-19.
Ellume CEO and founder Dr Sean Parsons warmly welcomed the State Government’s commitment to local manufacturing. Dr Parsons said, “Our technology is world class and the State Government’s investment boost will mean we can take our ground-breaking COVID-19 tests to the world”.
Ellume’s range of rapid diagnostic products serve to address the unprecedented global demand for fast, accurate diagnostic tests for infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19.
To meet anticipated demand, Ellume will use the State Government grant to expand its current manufacturing facility in Brisbane, already the largest of its kind in the Southern Hemisphere. The project is expected to support over 500 jobs when fully operational, with up to an additional 200 jobs created during construction.
This investment will enable the company to onshore and upscale as much of the critical component manufacturing back into Queensland as is practicable.
Ellume is on track to produce 100,000 tests per day from next month, and over 250,000 tests per day by March 2021. Ellume plans to manufacture and deliver in excess of 20 million Ellume COVID-19 tests within the first half of 2021.
Dr Parsons thanked the Premier Annastacia Palaszczuk and Treasurer Cameron Dick for supporting the company’s commitment to developing locally manufactured world-leading and life-saving diagnostics.
ENDS
Investors | Media & General Inquiries |
Dr Sean Parsons Founder & Managing Director E: sean.parsons@ellumehealth.com M: +61 7 3393 1448 | Patrick Condren Media Relations E: patrick.condren@ellumehealth.com M: +61 405 186 630 |